CClinicalTrials.gg
CompletedNCT01889368Updated Jun 27, 2017

Effect of a Grape Seed Extract (GSE) on Insulin Resistance

An interventional study of Grape Seed Extract and Placebo in Metabolic Syndrome, sponsored by University of California, Davis. Completed at 1 site in United States. Open to participants aged 20 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-06-27.

Sponsored by University of California, Davis · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
19
Allocation
Randomized
Ages
20 Years to 70 Years
Sex
All
01

Study summary

In people with the metabolic syndrome, the investigators hypothesize that administration of a single 300 mg dose of a grape seed extract (GSE) will reduce insulin resistance (how well cells in the body can take up and use glucose), oxidative stress, and the amount of oxidized LDL in the blood during a 24 hour period. These measurements will be assessed at hourly intervals during the 24 hour study day protocol. Additionally, the investigators hypothesize that daily administration of 300 mg of GSE for 30 days will decrease baseline insulin resistance, oxidative stress, and the level of oxidized LDL in the blood.

Read the detailed description

In people with the metabolic syndrome, the investigators hypothesize that administration of a single 300 mg dose of a grape seed extract (GSE) will reduce insulin resistance (how well cells in the body can take up and use glucose), oxidative stress, and the amount of oxidized LDL in the blood during a 24 hour period. Each of these can be elevated after eating high fat meals, which are commonly found in the average Western diet. To better assess the impact of these high fat eating patterns, three standardized high fat meals will be served during the study day: breakfast, lunch, and dinner. Measurements in the blood will be assessed at hourly intervals during the 24 hour study day protocol. Additionally, the investigators hypothesize that daily administration of 300 mg of GSE for 30 days will decrease baseline insulin resistance, oxidative stress, and the level of oxidized LDL in the blood when this 24 hour study day protocol is repeated and breakfast, lunch, and dinner are again served.

Insulin resistance will be measured using a comparison of insulin and glucose levels in the blood. Oxidative stress, a measure of inflammation, will be measured by cytokines levels in the blood. The level of oxidized LDL will be measured in the blood. The investigators also plan to undertake a subsidiary pharmacokinetic study on the various polymers which are known to be present in grape seed extracts to determine their bio-availability and their relationship to the biological effects observed.

02

Conditions studied

  • Metabolic Syndrome

Keywords

  • Insulin resistance
  • Central adiposity
  • Elevated blood pressure
  • Vascular reactivity
  • Elevated triglycerides
  • Low high-density lipoprotein (HDL)
03

In context

Metabolic Syndrome

1,964 studies on the registry are indexed under Metabolic Syndrome; 330 are open to participants now.

This study's enrollment of 19 is below the median of 60 across 1,460 interventional studies indexed under Metabolic Syndrome.

Browse Metabolic Syndrome studies →

Lead sponsor

University of California, Davis is the lead sponsor of 798 studies on the registry; 146 are open to participants now.

Of its 65 completed or terminated interventional studies of FDA-regulated products, 43 (66%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Metabolic Syndrome, based on subject meeting at least 3 of the following criteria:
  • Abdominal obesity with waist circumference > 40 inches in men or > 35 inches in women,
  • Pre-hypertension with blood pressure > 135/85,
  • Fasting blood glucose levels above 110 mg/dl,
  • Plasma triglyceride levels in excess of 150 mg/dl,
  • HDL levels below 40 mg/dl in men or 50 mg/dl in women.

Exclusion criteria

Exclusion Criteria:

  • Any known systemic disease,
  • Diabetes,
  • Alcohol consumption > 1-2 drinks/week,
  • Taking any medications or supplements that will affect metabolism, their ability to exercise or oxidative status,
  • Smokers,
  • Female subjects having abnormal menstrual cycles, taking oral contraceptives, pregnant or lactating.
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
19 participants (actual)

Study arms

  • Active comparator
    Grape Seed Extract

    This is a 30 day arm. At the baseline study visit, subjects will consume one 300 mg capsule of MegaNatural Gold followed by 3 high fat meals: breakfast, lunch, and dinner. Blood will be drawn at specified intervals throughout the day. Flow mediated dialysis will be performed before breakfast and again 1.5 hours later, after capsule consumption and breakfast. A minimum 14 day washout period will be between arms if this is the first arm in the randomized cross-over.

    Dietary Supplement: Grape Seed Extract

  • Placebo comparator
    Placebo

    This is a 30 day arm. At the baseline study visit, subjects will consume one placebo (maltodextrin) capsule followed by 3 high fat meals: breakfast, lunch, and dinner. Blood will be drawn at specified intervals throughout the day. Flow mediated dialysis will be performed before breakfast and again 1.5 hours later, after capsule consumption and breakfast. A minimum 14 day washout period will be between arms if this is the first arm in the randomized cross-over.

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementGrape Seed Extract

    300 mg capsule of Grape Seed Extract; 1 capsule will be consumed for an acute post-prandial study day and 1 capsule will be consumed daily for 30 days.

    Also known as: MegaNatural Gold

  • Dietary supplementPlacebo

    300 mg capsule of maltodextrin; 1 capsule will be consumed for an acute post-prandial study day and 1 capsule will be consumed daily for 30 days.

    Also known as: Maltodextrin

06

What researchers measure

Primary outcomes

  1. Changes in insulin resistance

    Insulin resistance will be assessed by comparing the baseline fasting insulin concentration to the fasting insulin concentration after intervention period of 30 days; the Homeostatic Model Assessment (HOMA) value will be utilized for comparisons.

    Time frame: Baseline and 30 days

Secondary outcomes

  1. Changes in oxidized LDL (oxLDL) concentrations

    Changes in oxLDL concentrations will be assessed by ELISA methodology. Changes in the 24 hour post-prandial response will be assessed at one hour intervals during the post-prandial study days, after capsule consumption and eating 3 high fat meals.

    Time frame: Baseline and 24 hour post-prandial response

  2. Changes in oxidative stress

    Changes in the 24 hour post-prandial oxidative stress response will be assessed at one hour intervals during the post-prandial study days, after capsule consumption and eating 3 high fat meals. Changes in oxidative stress will be assessed by measuring cytokine production using ELISA methodology.

    Time frame: Baseline and 24 hour post-prandial response

  3. Changes in vascular stress

    Changes in oxidative stress will be assessed by flow mediated dialysis (FMD). Changes will be assessed at baseline and one hour after capsule consumption and eating a high fat breakfast meal.

    Time frame: Baseline and 1 hour post-prandial

  4. Changes in insulin response

    Changes in the 24 hour post-prandial insulin response will be assessed at one hour intervals during the post-prandial study days, after capsule consumption and eating 3 high fat meals.

    Time frame: Baseline and 24 hour post-prandial response

  5. Changes in oxidized LDL (oxLDL) concentrations

    Changes in oxLDL concentrations will be assessed by ELISA methodology. Changes in the 24 hour post-prandial response will be assessed at one hour intervals during the post-prandial study days, after capsule consumption and eating 3 high fat meals. The response from the baseline visit will be compared to the response obtained during the day 30 visit.

    Time frame: Baseline and 30 days

  6. Changes in insulin response

    Changes in the 24 hour post-prandial insulin response will be assessed at one hour intervals during the post-prandial study days, after capsule consumption and eating 3 high fat meals. The response from the baseline visit will be compared to the response obtained during the day 30 visit.

    Time frame: Baseline and 30 days

  7. Changes in oxidative stress

    Changes in the 24 hour post-prandial oxidative stress response will be assessed at one hour intervals during the post-prandial study days, after capsule consumption and eating 3 high fat meals. Changes in oxidative stress will be assessed by measuring cytokine production using ELISA methodology. The response from the baseline visit will be compared to the response obtained during the 30 day visit.

    Time frame: Baseline and 30 days

  8. Changes in vascular stress

    Changes in oxidative stress will be assessed by flow mediated dialysis (FMD). Changes will be assessed at baseline and one hour after capsule consumption and eating a high fat breakfast meal. Results obtained during the first post-prandial study visit will be compared to those obtained 30 days later.

    Time frame: Baseline and 30 days

07

Study locations

1 site
  • VA Hospital, Mather
    Mather, California 95655, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 27, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01889368
Lead sponsor
University of California, Davis
Collaborators
Illinois Institute of Technology
Responsible party
Sponsor
First posted
Jun 28, 2013
Start date
Nov 2012
Primary completion
Mar 2015
Completion
Mar 2015
Last update
Jun 27, 2017

Study contacts

Chulani T Kappagoda, MD, PhD
principal investigator · University of California, Davis

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion